Top

Archives of Gynecology and Obstetrics

Published in:

01-01-2011 | General Gynecology

Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids

Authors: Efser Oztas, Gulay Kurtay

Published in: Archives of Gynecology and Obstetrics | Issue 1/2011

Abstract

Objective

To investigate the effects of raloxifene, on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in healthy postmenopausal women.

Methods

We studied the effect of raloxifene, on serum lipids and hs-CRP in 85 healthy postmenopausal women. Participants were randomly assigned to 60 mg daily raloxifene (43 subjects) for 6 months; the rest of the subjects were in the control group. Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglyceride and hs-CRP levels were measured at baseline and at the sixth month in both groups.

Results

Raloxifene treatment resulted in a 26% reduction in serum hs-CRP concentrations at the sixth month, compared with the baseline levels (P < 0.05). At the sixth month, TC and LDL-C levels were significantly reduced by 60 mg daily raloxifene (6.8 and 5.6%, respectively) when compared with both the baseline levels and the control group.

Conclusion

The results of our study showed that raloxifene at a dose of 60 mg daily reduces serum TC, LDL-C and hs-CRP levels significantly in healthy postmenopausal women. According to the results of the current study, we suggest that raloxifene may have a favorable effect on the prevention of cardiovascular disease in healthy postmenopausal women.

Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of Framingham population. Am J Heart 111:383–390CrossRef

Gohlke-Barwolf C (2000) Coronary artery disease—is menopause a risk factor? Basic Res Cardiol 95(Suppl 1):77–83CrossRef

Heart, Estrogen/progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280(7):605–613CrossRef

Heart, Estrogen/progestin Replacement Study (HERS) Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):49–57CrossRef

Cherry N, Gilmour K, Hannaford P (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360(9350):2001–2008CrossRefPubMed

Writing Group For The Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef

The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRef

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126CrossRefPubMed

Hanson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRef

10.

Fan J, Watanabe T (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10:63–71PubMed

11.

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1999) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336(14):973–979CrossRef

12.

Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20):2007–2011PubMed

13.

Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed

14.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2000) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565CrossRef

15.

Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21–29PubMed

16.

Saitta A, Morabito N, Frisina N (2001) Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 19(1):57–74CrossRefPubMed

17.

Walsh BW, Cox DA, Sashegyi A (2001) Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88(7):825–828CrossRefPubMed

18.

Yasui T, Uemura H, Hyodo S, Yamada M, Yamamoto S, Maegawa M, Tsuchiya N, Noguchi M, Yuzurihara M, Kase Y, Irahara M (2009) Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women. Atherosclerosis 204(2):471–475CrossRefPubMed

19.

Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287(7):847–857CrossRefPubMed

20.

Griffiths KA, Sader MA, Skilton MR (2003) Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 42(4):698–704CrossRefPubMed

21.

Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008) Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 6(6):928–934CrossRefPubMed

22.

Blumenthal RS, Baranowski B, Dowsett SA (2004) Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 147(5):783–789CrossRefPubMed

23.

Barrett-Connor E, Ensrud KE, Harper K (2003) Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25(3):919–930CrossRefPubMed

24.

De Leo W, la Marca A, Morgante G (2001) Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184(3):350–353CrossRefPubMed

25.

Walsh BW, Kuller LH, Wild RA (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279(18):1445–1451CrossRefPubMed

26.

Johnston CC, Bjarnason NH, Cohen FJ (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160(22):3444–3450CrossRefPubMed

27.

Anderson PW, Cox DA, Sashegyi A (2001) Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 39(1):71–77CrossRefPubMed

28.

Delmas PD, Bjarnason NH, Mitlak BH (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641–1647CrossRefPubMed

29.

Piperi C, Kalofoutis C, Lagogianni I, Troupis G, Kalofoutis A (2004) Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Mol Cell Biochem 261(1–2):71–75CrossRefPubMed

30.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137CrossRefPubMed

31.

Toss H, Lindahi B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive proteinlevels in unstable coronary artery disease. Circulation 96:4204–4210PubMed

32.

Tracy RP, Lemaitre RN, Psaty BM (1997) Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol 17:1121–1127PubMed

33.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMed

34.

Herrington DM, Brosnihan KB, Pusser BE (2001) Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 86(9):4216–4222CrossRefPubMed

35.

Walsh BW, Paul S, Wild RA (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85(1):214–218CrossRefPubMed

36.

Blum A, Cannon RO (2001) Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men. Ann N Y Acad Sci 949:168–174CrossRefPubMed

37.

de Valk-de Roo GW, Stehouwer CD, Meijer P (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19(12):2993–3000PubMed

Title: Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids
Authors: Efser Oztas
Gulay Kurtay
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 1/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-1292-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis

Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration

Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients

Misoprostol and termination of pregnancy: is there a need for ultrasound screening in a general population to assess the risk for adverse outcome in cases of uterine anomaly?

Bipolar vessel sealing increases operative safety in laparoscopic-assisted vaginal hysterectomy

Transvaginal NOTES with semi-rigid and rigid endoscopes that allow adjustable viewing angles